READD-ADSP: Building a Global Genetic Resource to Understand Alzheimer’s in Diverse Populations
Official title: Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD-ADSP)
Funded at University of Miami School of Medicine · NIH-11563838 · Data updated 2026-11-12
A large-scale project to create a global genetic resource to study Alzheimer’s disease in people of African, Afro-American, and Hispanic/Latino ancestry, helping researchers uncover why risk differs across groups.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $349,233 |
| NIH project number | 3U19AG074865-05S9 |
| Project ID | NIH-11563838 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals of African, Afro-American, or Hispanic/Latino ancestry who are willing to participate in genetic and clinical data collection for Alzheimer’s disease research.
✕Less likely to help
Participants not represented by these ancestry groups or those not expressing interest in genetic data sharing may observe limited direct benefit.
What this research studies
This NIH grant aims to assemble and harmonize clinical, phenotypic, and genetic data from 13,000 individuals across Africa, African American, and Hispanic/Latino groups to study the genetic causes of Alzheimer’s disease. Researchers will recruit participants, collect samples, and genotype them, then integrate these data with existing AD genomics efforts to enable richer analyses. Two hypothesis-driven projects will use the resource to begin unraveling genetic contributors to AD in underrepresented populations. The work is designed to improve understanding of ancestry-related differences in risk and to lay the groundwork for more inclusive future research and therapies.
Why it matters
Potential benefit: If successful, this resource could lead to more accurate risk profiling and previously unseen targets for therapies that account for diverse genetic backgrounds.
How similar studies have gone: Prior AD genomics efforts have shown value in diverse cohorts, and this resource builds on that foundation with a much larger, harmonized dataset.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Pericak-Vance, Margaret a. — University of Miami School of Medicine
- Study coordinator: Pericak-Vance, Margaret a.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.